ライフサイエンスコーパス: alcoholic hepatitis

1 tis, primary biliary cholangitis, and severe alcoholic hepatitis).

2 or alcoholic liver diseases and severe acute alcoholic hepatitis.

3 athologies, such as autoimmune hepatitis and alcoholic hepatitis.

4 er diseases such as autoimmune hepatitis and alcoholic hepatitis.

5 after liver transplantation in patients with alcoholic hepatitis.

6 l mechanism underlying IL-8 up-regulation in alcoholic hepatitis.

7 m is a potential therapeutic target in acute alcoholic hepatitis.

8 ronic-binge ethanol feeding or patients with alcoholic hepatitis.

9 be an effective treatment for patients with alcoholic hepatitis.

10 effective for the treatment of patients with alcoholic hepatitis.

11 tes to pathogenesis and clinical sequelae of alcoholic hepatitis.

12 favored for carefully selected patients with alcoholic hepatitis.

13 patients with fulminant hepatic failure and alcoholic hepatitis.

14 biological markers of deleterious outcome in alcoholic hepatitis.

15 can be recommended as standard therapies for alcoholic hepatitis.

16 remain the cornerstones in the treatment of alcoholic hepatitis.

17 in formulating safe, effective therapies for alcoholic hepatitis.

18 ed with increased mortality in patients with alcoholic hepatitis.

19 positive cells were also greater in NASH vs. alcoholic hepatitis.

20 re markedly increased in patients with acute alcoholic hepatitis.

21 with normal liver 11 pg/mg) in patients with alcoholic hepatitis.

22 eful to predict the outcome in patients with alcoholic hepatitis.

23 oves survival in select patients with severe alcoholic hepatitis.

24 ce showed a similar pattern as seen in human alcoholic hepatitis.

25 its deficiency in the pathogenesis of severe alcoholic hepatitis.

26 irrhosis, with highest risk in patients with alcoholic hepatitis.

27 an NASH, primary sclerosing cholangitis, and alcoholic hepatitis.

28 d with the development, but not severity, of alcoholic hepatitis.

29 utic approach is effective for patients with alcoholic hepatitis.

30 disease and with mortality in patients with alcoholic hepatitis.

31 okine ligand types 5 (CCL5) in patients with alcoholic hepatitis.

32 tion ex vivo in whole blood of patients with alcoholic hepatitis.

33 mes and increased mortality in patients with alcoholic hepatitis.

34 ssue and serum samples from 54 patients with alcoholic hepatitis.

35 timize the therapeutic development in severe alcoholic hepatitis.

36 17 could be a viable approach in attenuating alcoholic hepatitis.

37 ADH-specific cellular immunity is present in alcoholic hepatitis.

38 ne did not improve survival in patients with alcoholic hepatitis.

39 argeted therapies to inhibit Th1 immunity in alcoholic hepatitis.

40 of whom 15 had histopathological evidence of alcoholic hepatitis (10 cirrhotic) and 9 no evidence of

41 the fecal microbial ecology associated with alcoholic hepatitis, (2) relate microbiome changes to di

42 In patients with alcoholic hepatitis, 4-week treatment with pentoxifyllin

43 epatitis (10 cirrhotic) and 9 no evidence of alcoholic hepatitis (5 cirrhotic); other controls includ

44 or pentoxifylline is recommended for severe alcoholic hepatitis, a life-threatening disease.

45 PTX3 levels were increased in patients with alcoholic hepatitis, a prototypic acute-on-chronic condi

46 ed blood samples from 20 patients with acute alcoholic hepatitis (AAH), 16 patients with stable advan

47 erapy has shown some benefit in severe acute alcoholic hepatitis (AAH); however, this is limited by u

48 onsortium of Early Liver Transplantation for Alcoholic Hepatitis (ACCELERATE-AH) cohort, we aimed to

49 : recipient's age, hepatocellular carcinoma, alcoholic hepatitis, acute-on-chronic liver failure, hil

50 nically relevant progenitor markers in human alcoholic hepatitis (AH) and hepatocellular carcinoma (H

51 hat neutrophilic NCF1-dependent ROS promoted alcoholic hepatitis (AH) by inhibiting AMP-activated pro

52 Although mortality due to acute alcoholic hepatitis (AH) correlates with Model for End-S

53 Alcoholic hepatitis (AH) develops in only a small propor

54 Alcoholic hepatitis (AH) frequently progresses to multip

55 Severe alcoholic hepatitis (AH) has high mortality.

56 BACKGROUND & AIMS: Patients with severe alcoholic hepatitis (AH) have a high risk of death withi

57 Epidemiologic studies of alcoholic hepatitis (AH) have been hindered by the lack

58 Alcoholic hepatitis (AH) is a distinct spectrum of alcoh

59 Alcoholic hepatitis (AH) is a life-threatening condition

60 Severe alcoholic hepatitis (AH) is a life-threatening disease f

61 Alcoholic hepatitis (AH) is a severe condition developed

62 Alcoholic hepatitis (AH) is a severe manifestation of al

63 Alcoholic hepatitis (AH) is a syndrome of jaundice and l

64 Alcoholic hepatitis (AH) is associated with liver neutro

65 We recently showed that alcoholic hepatitis (AH) is characterized by dedifferent

66 Alcoholic Hepatitis (AH) is major source of alcohol-rela

67 Alcoholic hepatitis (AH) is the most severe form of alco

68 Alcoholic hepatitis (AH) is the most severe form of alco

69 sessing severity of disease in patients with alcoholic hepatitis (AH) is useful for predicting mortal

70 Human alcoholic hepatitis (AH) liver samples were used for ele

71 We found impaired autophagy both in ALD and alcoholic hepatitis (AH) mouse models and human livers w

72 The diagnosis of alcoholic hepatitis (AH) often requires a transjugular l

73 Mortality in patients with alcoholic hepatitis (AH) remains high, and although cort

74 Human alcoholic hepatitis (AH) samples were also used for immu

75 lored the role of intrahepatic LCN2 in human alcoholic hepatitis (AH) with advanced fibrosis and port

76 Steroids improve the outcome in alcoholic hepatitis (AH), but up to 40% of patients fail

77 All had clinically diagnosed severe alcoholic hepatitis (AH), no prior diagnosis of liver di

78 at result in endotoxemia, such as sepsis and alcoholic hepatitis (AH), often are accompanied by chole

79 the transcriptome analysis of patients with alcoholic hepatitis (AH), osteopontin (OPN) as one of th

80 In alcoholic hepatitis (AH), the degree of DR expansion cor

81 s on effective therapeutic interventions for alcoholic hepatitis (AH), the most severe form of alcoho

82 ansplantation (LT) is a viable treatment for alcoholic hepatitis (AH).

83 h those with alcoholic cirrhosis (AC) and/or alcoholic hepatitis (AH).

84 atment in a cohort of 41 patients with acute alcoholic hepatitis (AH).

85 crophages are central to the pathogenesis of alcoholic hepatitis (AH).

86 stem to determine prognoses of patients with alcoholic hepatitis (AH).

87 ts based on the diagnosis of the explant (46 alcoholic hepatitis and 138 alcoholic cirrhosis) and dia

88 se (n = 58), 43 had histological features of alcoholic hepatitis and 15 (25%) did not.We aimed to det

89 t both listing as well as of the explant (11 alcoholic hepatitis and 33 alcoholic cirrhosis).

90 Patients with suspected alcoholic hepatitis and a Discriminant Function >/=32 un

91 s, but safe and effective therapies for both alcoholic hepatitis and alcoholic cirrhosis are still wa

92 se but safe and effective therapies for both alcoholic hepatitis and alcoholic cirrhosis have yet to

93 Five-year graft and patient survival of alcoholic hepatitis and alcoholic cirrhosis patients wer

94 oholic cirrhosis were studied, 27 with acute alcoholic hepatitis and cirrhosis, in whom hepatic venou

95 for the development of advanced ALD such as alcoholic hepatitis and cirrhosis.

96 to produce safe and effective therapies for alcoholic hepatitis and for reversing cirrhosis.

97 to determine the likelihood of histological alcoholic hepatitis and guide treatment.

98 n-1alpha in liver samples from patients with alcoholic hepatitis and individuals without alcoholic he

99 e interleukin-8 (IL-8) is highly elevated in alcoholic hepatitis and levels correlate with the degree

100 Liver samples from alcoholic hepatitis and primary biliary cholangitis pati

101 Patients with a clinical diagnosis of alcoholic hepatitis and severe disease were randomly ass

102 al hepatitis, typically in Asia, and drug or alcoholic hepatitis and variceal hemorrhage in the West.

103 aceae and Ruminococcaceae) were decreased in alcoholic hepatitis, and a similar decrease was observed

104 sease, which includes alcoholic fatty liver, alcoholic hepatitis, and alcoholic cirrhosis.

105 use results in the development of steatosis, alcoholic hepatitis, and cirrhosis.

106 osis was assessed in NASH, simple steatosis, alcoholic hepatitis, and controls without liver disease

107 Steatosis, alcoholic hepatitis, and fibrosis are the 3 pathologic f

108 e associated with obesity, type II diabetes, alcoholic hepatitis, and nonalcoholic steatohepatitis.

109 ants include bacterial and viral infections, alcoholic hepatitis, and surgery, but in more than 40% o

110 Steroid use and nutrition for alcoholic hepatitis are being refined, and the validity

111 a on liver transplantation for patients with alcoholic hepatitis are limited.

112 rule, the patients admitted for severe acute alcoholic hepatitis are not eligible for liver transplan

113 ALCoholic Hepatitis Artificial INtelligence Ensemble sco

114 e improved 30-day survival for those with an ALCoholic Hepatitis Artificial INtelligence Ensemble sco

115 The ALCoholic Hepatitis Artificial INtelligence Ensemble sco

116 ents were stratified into two groups: severe alcoholic hepatitis as first liver decompensation (Group

117 ere heavy drinkers with severe biopsy-proven alcoholic hepatitis, as indicated by recent onset of jau

118 rinking post-OLT, and three of those died of alcoholic hepatitis at nine months, 2.5 and 3.5 years af

119 sponses in various liver diseases, including alcoholic hepatitis, autoimmune hepatitis, and primary b

120 precipitating event (active alcoholism/acute alcoholic hepatitis, bacterial infection, and others); (

121 short-term and long-term survival in severe alcoholic hepatitis based on baseline disease severity,

122 registrations and liver transplantation for alcoholic hepatitis before and during the COVID-19 pande

123 ted in increasing mortality in patients with alcoholic hepatitis but the underlying mechanisms are no

124 both recommended for the treatment of severe alcoholic hepatitis, but uncertainty about their benefit

125 test the hypothesis that LBP is involved in alcoholic hepatitis by comparing LBP knockout and wild-t

126 o patients with a variety of liver diseases (alcoholic hepatitis, cirrhosis, hepatocellular carcinoma

127 Within the alcoholic hepatitis cohort, patients with levels of at l

128 blood mononuclear cells of patients with ALD/alcoholic hepatitis compared to controls.

129 alcoholic hepatitis and individuals without alcoholic hepatitis (controls).

130 tocol showed that early transplant in severe alcoholic hepatitis could improve survival with low inci

131 Severe alcoholic hepatitis, defined as a modified discriminant

132 In patients with moderate to severe alcoholic hepatitis, etanercept was associated with a si

133 blood monocytes isolated from patients with alcoholic hepatitis, expression of TNFalpha mRNA was rob

134 ng organ inflammation, including in viral or alcoholic hepatitis, fatty liver disease, allograft reje

135 e spectrum of ALD includes simple steatosis, alcoholic hepatitis, fibrosis, cirrhosis, and superimpos

136 Proliferative anti-ADH immune responses in alcoholic hepatitis focused on individual epitopic regio

137 se patients with a histological diagnosis of alcoholic hepatitis from those without, and assess poten

138 In the clinical setting of severe acute alcoholic hepatitis, further studies are needed for the

139 Liver samples from patients with alcoholic hepatitis had reduced levels of SIRT1 and a hi

140 Patients with alcoholic hepatitis had significantly higher ASCA levels

141 nts with alcohol-use disorder, patients with alcoholic hepatitis have increased faecal numbers of E.

142 ared with alcoholic cirrhosis, patients with alcoholic hepatitis have similar posttransplantation gra

143 a semiquantitative scoring system called the Alcoholic Hepatitis Histologic Score (AHHS) was develope

144 ommon, however, it was associated with fatal alcoholic hepatitis in 50% of patients.

145 m liver biopsy showed histologic features of alcoholic hepatitis in addition to bridging fibrosis or

146 tion of lipin-1 ameliorated inflammation and alcoholic hepatitis in mice via activation of endocrine

147 levels, and a histologic picture similar to alcoholic hepatitis in the absence of alcohol abuse.

148 In patients with alcoholic hepatitis, increased expression of p21, but no

149 t to transplant selected patients with acute alcoholic hepatitis, initiated in October 2012.

150 Alcoholic hepatitis is a cause of major morbidity and mo

151 Alcoholic hepatitis is a clinical syndrome characterized

152 Early liver transplantation for alcoholic hepatitis is a potentially life-saving treatme

153 Alcoholic hepatitis is a severe and life-threatening for

154 Acute alcoholic hepatitis is associated with significant lymph

155 Alcoholic hepatitis is characterised by florid hepatic i

156 Acute alcoholic hepatitis is characterized by disproportionate

157 Alcoholic hepatitis is characterized by parenchymal neut

158 Symptomatic alcoholic hepatitis is characterized by rapid onset of j

159 The role of the intestinal microbiome in alcoholic hepatitis is not established.

160 in-arginine-methyltransferase-1 increased in alcoholic hepatitis livers.

161 e fecal microbiome in patients with moderate alcoholic hepatitis (MAH) or severe alcoholic hepatitis

162 that parenchymal neutrophil infiltration in alcoholic hepatitis may be determined by selective upreg

163 Forty-eight patients with moderate to severe alcoholic hepatitis (Model for End-Stage Liver Disease s

164 PBMCs were collected from 15 patients with alcoholic hepatitis (modified Maddrey's discriminant fun

165 that new therapeutic development for severe alcoholic hepatitis must target liver injury in the shor

166 ach of the histologically confirmed cases of alcoholic hepatitis (n = 43) were compared to those with

167 thrombosis (n = 6), hepatoma (n = 3), florid alcoholic hepatitis (n = 6), and refusal to give consent

168 hs at 8 United States centers as part of the Alcoholic Hepatitis Network (AlcHepNet) consortium.

169 e treatment of inflammatory diseases such as alcoholic hepatitis, nonalcoholic steatohepatitis, and p

170 For alcoholic hepatitis, nutritional support is the mainstay

171 ion, such as those observed in patients with alcoholic hepatitis or cirrhosis.

172 ) and K2 (OR, 9.280 [95% CI, 0.987-87.250]), alcoholic hepatitis (OR, 7.435 [95% CI, 1.397-39.572]),

173 expression of SEMA3C in patients with NASH, alcoholic hepatitis, or HBV-induced hepatitis discrimina

174 cterized by liver inflammation, fatty liver, alcoholic hepatitis, or liver cirrhosis.

175 a ADMA and SDMA were significantly higher in alcoholic hepatitis patients and in nonsurvivors.

176 PBMs isolated from alcoholic hepatitis patients had high expression of SIRT

177 Alcoholic hepatitis patients have higher portal pressure

178 , analysis of circulating EVs from plasma of alcoholic hepatitis patients revealed increased numbers

179 ic dimethylarginine (SDMA), are increased in alcoholic hepatitis patients, and determined any relatio

180 but results in negative clinical outcomes in alcoholic hepatitis patients.

181 r decrease was observed in fecal SCFAs among alcoholic hepatitis patients.

182 tinal mycobiota in a cohort of patients with alcoholic hepatitis, patients with alcohol use disorder,

183 findings that are identical to those seen in alcoholic hepatitis; patients with NASH, however, do not

184 icosteroids remain the mainstay treatment in alcoholic hepatitis pending the results from large multi

185 se results indicate that nimodipine prevents alcoholic hepatitis, possibly by inhibition of endotoxin

186 addition to being a potential biomarker for alcoholic hepatitis, PTX3 participates in the wound-heal

187 PBMCs from seven of 15 patients with alcoholic hepatitis recognised one to three ADH peptides

188 The cornerstone of treatment for alcoholic hepatitis remains as it was 40 years ago: abst

189 o patients died of myocardial infarction and alcoholic hepatitis, respectively.

190 Severe alcoholic hepatitis (SAH) is often a progressive disease

191 l infiltration has been implicated in severe alcoholic hepatitis (SAH) pathogenesis; however, the mec

192 alterations in circulating albumin in severe alcoholic hepatitis (SAH) patients and their contributio

193 The pathogenesis of antibodies in severe alcoholic hepatitis (SAH) remains unknown.

194 moderate alcoholic hepatitis (MAH) or severe alcoholic hepatitis (SAH) was compared with healthy cont

195 nfections are common in patients with severe alcoholic hepatitis (SAH), but little information is ava

196 nfections are common in patients with severe alcoholic hepatitis (SAH), but little information is ava

197 Patient MELD score and Glasgow Alcoholic Hepatitis score (GAHS) correlated with endotox

198 rly linked to key clinical symptoms of acute alcoholic hepatitis such as fever, neutrophilia, and was

199 holangitis, primary biliary cholangitis, and alcoholic hepatitis, suggesting IBA1 + CD163 low macroph

200 mmatory Th1 responses was more pronounced in alcoholic hepatitis than in alcoholic-related cirrhosis.

201 n the patients with histological features of alcoholic hepatitis than in those without.

202 trated in liver specimens from patients with alcoholic hepatitis, the AR up-regulation and elevated A

203 articularly advanced ALD (cirrhosis or acute alcoholic hepatitis), total abstinence from alcohol is t

204 no impact of the etiology of liver disease (alcoholic hepatitis versus alcoholic cirrhosis) on the g

205 Alcoholic hepatitis was associated with a distinct micro

206 th bacteria from the faeces of patients with alcoholic hepatitis, we investigated the therapeutic eff

207 r transplantation for a listing diagnosis of alcoholic hepatitis were matched for age, gender, ethnic

208 priate in highly select patients with severe alcoholic hepatitis who do not respond to medical therap

209 onsidered in a select group of patients with alcoholic hepatitis who fail to improve with medical the

210 tment of ArLD and its complications, such as alcoholic hepatitis, will allow a greater proportion of

211 ately differentiate patients with or without alcoholic hepatitis without liver biopsy.